BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

477 related articles for article (PubMed ID: 31546892)

  • 1. Can Botulinum Toxin A Still Have a Role in Treatment of Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Through Inhibition of Chronic Prostatic Inflammation?
    Chiang BJ; Kuo HC; Liao CH
    Toxins (Basel); 2019 Sep; 11(9):. PubMed ID: 31546892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inflammation is a target of medical treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia.
    De Nunzio C; Salonia A; Gacci M; Ficarra V
    World J Urol; 2020 Nov; 38(11):2771-2779. PubMed ID: 32060633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intraprostatic Botulinum Neurotoxin Type A Injection for Benign Prostatic Hyperplasia-A Spotlight in Reality.
    Hsu YC; Wang HJ; Chuang YC
    Toxins (Basel); 2016 Apr; 8(5):. PubMed ID: 27128942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of inflammation in lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) and its potential impact on medical therapy.
    Ficarra V; Rossanese M; Zazzara M; Giannarini G; Abbinante M; Bartoletti R; Mirone V; Scaglione F
    Curr Urol Rep; 2014 Dec; 15(12):463. PubMed ID: 25312251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostatic injection of botulinum toxin is not inferior to optimized medical therapy in the management of lower urinary tract symptoms due to benign prostatic hyperplasia: results of a randomized clinical trial.
    Robert G; Descazeaud A; Karsenty G; Saussine C; Azzouzi AR; de la Taille A; Desgrandchamps F; Faix A; Fourmarier M; Georget A; Benard A; Barry Delongchamps N
    World J Urol; 2018 Jun; 36(6):921-929. PubMed ID: 29383480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH).
    Gandaglia G; Briganti A; Gontero P; Mondaini N; Novara G; Salonia A; Sciarra A; Montorsi F
    BJU Int; 2013 Aug; 112(4):432-41. PubMed ID: 23650937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel Applications of OnabotulinumtoxinA in Lower Urinary Tract Dysfunction.
    Jhang JF; Kuo HC
    Toxins (Basel); 2018 Jun; 10(7):. PubMed ID: 29949878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transurethral intraprostatic Botulinum toxin-A injection: a novel treatment for BPH refractory to current medical therapy in poor surgical candidates.
    Hamidi Madani A; Enshaei A; Heidarzadeh A; Mokhtari G; Farzan A; Mohiti Asli M; Esmaeili S
    World J Urol; 2013 Feb; 31(1):235-9. PubMed ID: 22411419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient-reported outcomes in men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) treated with intraprostatic OnabotulinumtoxinA: 3-month results of a prospective single-armed cohort study.
    Sacco E; Bientinesi R; Marangi F; Totaro A; D'Addessi A; Racioppi M; Pinto F; Vittori M; Bassi P
    BJU Int; 2012 Dec; 110(11 Pt C):E837-44. PubMed ID: 22712582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging drugs to target lower urinary tract symptomatology (LUTS)/benign prostatic hyperplasia (BPH): focus on the prostate.
    Ückert S; Kedia GT; Tsikas D; Simon A; Bannowsky A; Kuczyk MA
    World J Urol; 2020 Jun; 38(6):1423-1435. PubMed ID: 31506747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained beneficial effects of intraprostatic botulinum toxin type A on lower urinary tract symptoms and quality of life in men with benign prostatic hyperplasia.
    Chuang YC; Chiang PH; Yoshimura N; De Miguel F; Chancellor MB
    BJU Int; 2006 Nov; 98(5):1033-7; discussion 1337. PubMed ID: 16956361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Botulinum toxin injection for lower urinary tract dysfunction.
    Kuo YC; Kuo HC
    Int J Urol; 2013 Jan; 20(1):40-55. PubMed ID: 22571329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Botulinum toxin-what urologic uses does the data support?
    Seth J; Khan MS; Dasgupta P; Sahai A
    Curr Urol Rep; 2013 Jun; 14(3):227-34. PubMed ID: 23625366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Qianliexin capsule exerts anti-inflammatory activity in chronic non-bacterial prostatitis and benign prostatic hyperplasia via NF-κB and inflammasome.
    Zang L; Tian F; Yao Y; Chen Y; Shen Y; Han M; Meng Z; Fan S; Zhang X; Cai T; Gao Q; Zhang Y; Lu J
    J Cell Mol Med; 2021 Jun; 25(12):5753-5768. PubMed ID: 33982874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia.
    Gacci M; Eardley I; Giuliano F; Hatzichristou D; Kaplan SA; Maggi M; McVary KT; Mirone V; Porst H; Roehrborn CG
    Eur Urol; 2011 Oct; 60(4):809-25. PubMed ID: 21726934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intraprostatic botulinum toxin type "A" injection in patients with benign prostatic hyperplasia and unsatisfactory response to medical therapy: A randomized, double-blind, controlled trial using urodynamic evaluation.
    Totaro A; Pinto F; Pugliese D; Vittori M; Racioppi M; Foschi N; Bassi PF; Sacco E
    Neurourol Urodyn; 2018 Mar; 37(3):1031-1038. PubMed ID: 28840969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Promise and the Pharmacological Mechanism of Botulinum Toxin A in Chronic Prostatitis Syndrome.
    Chen CH; Tyagi P; Chuang YC
    Toxins (Basel); 2019 Oct; 11(10):. PubMed ID: 31614473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome of Botulinum Toxin-A intraprostatic injection for benign prostatic hyperplasia induced lower urinary tract symptoms: A prospective multicenter study.
    Moussa AS; Ragheb AM; Abdelbary AM; Ibrahim RM; El Adawy MS; Aref A; Assem A; Elfayoumy H; Elzawy F
    Prostate; 2019 Aug; 79(11):1221-1225. PubMed ID: 31189024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Appearance of High Endothelial Venule-Like Vessels in Benign Prostatic Hyperplasia is Associated With Lower Urinary tract Symptoms.
    Inamura S; Shinagawa T; Hoshino H; Sakai Y; Imamura Y; Yokoyama O; Kobayashi M
    Prostate; 2017 May; 77(7):794-802. PubMed ID: 28181681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Botulinum toxin A injection to the bladder neck and urethra for medically refractory lower urinary tract symptoms in men without prostatic obstruction.
    Chen JL; Chen CY; Kuo HC
    J Formos Med Assoc; 2009 Dec; 108(12):950-6. PubMed ID: 20040460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.